Glybera

After treating only one person with the ground-breaking therapy, uniqure is giving up on Glybera and shifting all its commercial manufacturing to the US

The European Medicines Agency’s thumbs-down for rare disease treatment Glybera flies in the face of Commission policy. It’s also against the wishes of the European Parliament, and the impetus DG Sanco is putting into Orphan Drugs. Worse still, it’s bad for patients and kills innovation. By Nuala Moran.